Downregulation of HMGA-targeting microRNAs has a critical role in human pituitary tumorigenesis

Oncogene

Volumn 31, Issue 34, 2012, Pages 3857-3865

  Palmieri, D ^a   D'Angelo, D ^a   Valentino, T ^a   De Martino, I ^a   Ferraro, A ^a,d   Wierinckx, A ^b,c   Fedele, M ^a   Trouillas, J ^d,e   Fusco, A ^a,f  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b CENTRE DE RECHERCHE EN CANCÉROLOGIE DE LYON   (France)

^c UNIVERSITÉ DE LYON   (France)

^d LYON NEUROSCIENCE RESEARCH CENTER   (France)

^e UNIVERSITÉ LYON 1   (France)

^f CEINGE BIOTECNOLOGIE AVANZATE   (Italy)

Author keywords

HMGA; microRNA; pituitary adenoma

Indexed keywords

HIGH MOBILITY GROUP A PROTEIN; HIGH MOBILITY GROUP A1 PROTEIN; HIGH MOBILITY GROUP A2 PROTEIN; MESSENGER RNA; MICRORNA; MICRORNA 15A; MICRORNA 16; MICRORNA 196A2; MICRORNA 26A; MICRORNA LET 7A; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ANIMAL CELL; ARTICLE; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION REGULATION; GENE LOCUS; GENE OVEREXPRESSION; GENE TARGETING; HISTOLOGY; HUMAN; HUMAN TISSUE; HYPOPHYSIS TUMOR; NONHUMAN; PITUITARY TUMORIGENESIS; PRIORITY JOURNAL; RAT; TRANSGENIC MOUSE;

3' UNTRANSLATED REGIONS; ANIMALS; BASE SEQUENCE; BINDING SITES; BLOTTING, WESTERN; CELL LINE; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; HMGA PROTEINS; HMGA1A PROTEIN; HMGA2 PROTEIN; HUMANS; MICRORNAS; PITUITARY NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SEQUENCE HOMOLOGY, NUCLEIC ACID;

MUS MUSCULUS; RATTUS;

EID: 84865428087     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.557     Document Type: Article

References (41)

1. Ashar HR, Fejzo MS, Tkachenko A, Zhou X, Fletcher JA, Weremowicz S et al. (1995). Disruption of the architectural factor HMGI-C: DNA-binding AT hook motifs fused in lipomas to distinct transcriptional regulatory domains. Cell 82: 57-65.
2. Baldassarre G, Fedele M, Battista S, Vecchione A, Klein-Szanto AJ, Santoro M et al. (2001). Onset of natural killer cell lymphomas in transgenic mice carrying a truncated HMGI-C gene by the chronic stimulation of the IL-2 and IL-15 pathway. Proc Natl Acad Sci USA 98: 7970-7975. (Pubitemid 32642671)
3. Bartel DP. (2004). MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281-297.
4. Berlingieri MT, Manfioletti G, Santoro M, Bandiera A, Visconti R, Giancotti V et al. (1995). Inhibition of hmgi-c protein synthesis suppresses retrovirally induced neoplastic transformation of rat thyroid cells. Mol Cell Biol 15: 1545-1553.
5. Berlingieri MT, Pierantoni GM, Giancotti V, Santoro M, Fusco A. (2002). Thyroid cell transformation requires the expression of the HMGA1 proteins. Oncogene 21: 2971-2980. (Pubitemid 34522896)
6. Bottoni A, Piccin D, Tagliati F, Luchin A, Zatelli MC, degli Uberti EC. (2005). miR-15a and miR-16-1 down-regulation in pituitary adenomas. J Cell Physiol 204: 280-285. (Pubitemid 40776831)
7. Calin GA, Croce CM. (2006). MicroRNA signatures in human cancers. Nat Rev Cancer 6: 857-866. (Pubitemid 44629897)
8. Chiappetta G, Avantaggiato V, Visconti R, Fedele M, Battista S, Trapasso F et al. (1996). High level expression of the HMGI (Y) gene during embryonic development. Oncogene 13: 2439-2446. (Pubitemid 27026027)
9. Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA, Beckers A. (2006). High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab 91: 4769-4775. (Pubitemid 44917305)
10. Daly AF, Tichomirowa MA, Beckers A. (2009). The epidemiology and genetics of pituitary adenomas. Best Pract Res Clin Endocrinol Metab 23: 543-554.
11. De Martino I, Visone R, Fedele M, Petrocca F, Palmieri D, Martinez Hoyos J et al. (2009a). Regulation of microRNA expression by HMGA1 proteins. Oncogene 28: 1432-1442.
12. De Martino I, Visone R, Palmieri D, Cappabianca P, Chieffi P, Forzati F et al. (2007). The Mia/Cd-rap gene expression is downregulated by the high-mobility group A proteins in mouse pituitary adenomas. Endocr Relat Cancer 14: 875-886. (Pubitemid 350074075)
13. De Martino I, Visone R, Wierinckx A, Palmieri D, Ferraro A, Cappabianca P et al. (2009b). HMGA proteins up-regulate CCNB2 gene in mouse and human pituitary adenomas. Cancer Res 69: 1844-1850.
14. Fedele M, Battista S, Kenyon L, Baldassarre G, Fidanza V, Klein-Szanto AJP et al. (2002). Overexpression of the HMGA2 gene in transgenic mice leads to the onset of pituitary adenomas. Oncogene 21: 3190-3198. (Pubitemid 34548089)
15. Fedele M, Fusco A. (2010). HMGA and cancer. Biochim Biophys Acta 1799: 48-54.
16. Fedele M, Palmieri D, Fusco A. (2010). HMGA2: a pituitary tumour subtype-specific oncogene? Mol Cell Endocrinol 326: 19-24.
17. Fedele M, Pentimalli F, Baldassarre G, Battista S, Klein-Szanto AJP, Kenyon L et al. (2005). Transgenic mice overexpressing the wild-type form of the HMGA1 gene develop mixed growth hormone/prolactin cell pituitary adenomas and natural killer cell lymphomas. Oncogene 24: 3427-3435. (Pubitemid 40756244)
18. Fedele M, Visone R, De Martino I, Troncone G, Palmieri D, Battista S et al. (2006). HMGA2 induces pituitary tumorigenesis by enhancing E2F1 activity. Cancer Cell 9: 459-471. (Pubitemid 43832192)
19. Fernandez A, Karavitaki N, Wass JA. (2010). Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol (Oxf) 72: 377-382.
20. Finelli P, Pierantoni GM, Giardino D, Losa M, Rodeschini O, Fedele M et al. (2002). The high mobility group A2 gene is amplified and overexpressed in human prolactinomas. Cancer Res 62: 2398-2405. (Pubitemid 34411724)
21. Fusco A, Fedele M. (2007). Roles of HMGA proteins in cancer. Nat Rev Cancer 7: 899-910. (Pubitemid 350165857)
22. Hebert C, Norris K, Scheper MA, Nikitakis N, Sauk JJ. (2007). High mobility group A2 is a target for miRNA-98 in head and neck squamous cell carcinoma. Mol Cancer 6: 5.
23. Johnson KR, Lehn DA, Reeves R. (1989). Alternative processing of mRNAs encoding mammalian chromosomal high-mobility-group proteins HMG-I and HMG-Y. Mol Cell Biol 5: 2114-2123. (Pubitemid 19117812)
24. Kovacs K, Horvath E. (1986). Pathology of growth hormone-producing tumors of the human pituitary. Semin Diagn Pathol 3: 18-33. (Pubitemid 16131708)
25. Kaddar T, Rouault JP, Chien WW, Chebel A, Gadoux M, Salles G et al. (2009). Two new miR-16 targets: caprin-1 and HMGA1, proteins implicated in cell proliferation. Biol Cell 101: 511-524.
26. Lagos-Quintana M, Rauhut R, Yalcin A, Meyer J, Lendeckel W, Tuschl T. (2002). Identification of tissue-specific microRNAs from mouse. Curr Biol 12: 735-739. (Pubitemid 34455427)
27. Lagana A, Forte S, Giudice A, Arena MR, Puglisi PL, Giugno R et al. (2009). miRo: a miRNA knowledge base. Database (Oxford) 2009: bap008.
28. Lee S, Jung JW, Park SB, Roh K, Lee SY, Kim JH et al. (2011). Histone deacetylase regulates high mobility group A2-targeting microRNAs in human cord blood-derived multipotent stem cell aging. Cell Mol Life Sci 68: 325-336.
29. Lee YS, Dutta A. (2007). The tumor suppressor microRNA let-7 represses the HMGA2 oncogene. Genes Dev 21: 1025-1030. (Pubitemid 46686471)
30. Livak KJ, Schmittgen TD. (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408. (Pubitemid 34164012)
31. Melmed S. (2011). Pathogenesis of pituitary tumors. Nat Rev Endocrinol 7: 257-266.
32. Monson JP. (2000). The epidemiology of endocrine tumours. Endocr Relat Cancer 7: 29-36. (Pubitemid 30305869)
33. Pierantoni GM, Fedele M, Pentimalli F, Benvenuto G, Pero R, Viglietto G et al. (2001). High mobility group I (Y) proteins bind HIPK2, a serine-threonine kinase protein which inhibits cell growth. Oncogene 20: 6132-6141. (Pubitemid 32964425)
34. Pierantoni GM, Finelli P, Valtorta E, Giardino D, Rodeschini O, Esposito F et al. (2005). High-mobility group A2 gene expression is frequently induced in non-functioning pituitary adenomas (NFPAs), even in the absence of chromosome 12 polysomy. Endocr Relat Cancer 12: 867-874. (Pubitemid 41815781)
35. Qian ZR, Asa SL, Siomi H, Siomi MC, Yoshimoto K, Yamada S et al. (2009). Overexpression of HMGA2 relates to reduction of the let-7 and its relationship to clinicopathological features in pituitary adenomas. Mod Pathol 22: 431-441.
36. Scala S, Portella G, Fedele M, Chiappetta G, Fusco A. (2000). Adenovirus-mediated suppression of HMG I (Y) protein synthesis as potential therapy of human malignant neoplasias. Proc Natl Acad Sci USA 97: 4256-4261. (Pubitemid 30226120)
37. Schoenmakers EF, Wanschura S, Mols R, Bullerdiek J, Van den Berghe H, Van de Ven WJ. (1995). Recurrent rearrangements in the high mobility group protein gene, HMGI-C, in benign mesenchymal tumours. Nat Genet 10: 436-444.
38. Thanos D, Du W, Maniatis T. (1993). The high mobility group protein HMG I (Y) is an essential structural component of a virus-inducible enhancer complex. Cold Spring Harb Symp Quant Biol 58: 73-81. (Pubitemid 24219466)
39. Thanos D, Maniatis T. (1992). The high mobility group protein HMG I (Y) is required for NF-kappa B-dependent virus induction of the human IFN-beta gene. Cell 71: 777-789.
40. Wang EL, Qian ZR, Rahman MM, Yoshimoto K, Yamada S, Kudo E et al. (2010). Increased expression of HMGA1 correlates with tumour invasiveness and proliferation in human pituitary adenomas. Histopathology 56: 501-509.
41. Zhou X, Benson KF, Ashar HR, Chada K. (1995). Mutation responsible for the mouse pygmy phenotype in the developmentally regulated factor HMGI-C. Nature 376: 771-774.